Citrate and albumin facilitate transferrin iron loading in the presence of phosphate.
暂无分享,去创建一个
Catalina Matias | Devin W Belnap | Michael T Smith | Michael G Stewart | Isaac F Torres | Andrew J Gross | Richard K Watt | A. Gross | R. K. Watt | C. Matias | Michael G. Stewart | I. Torres
[1] H. Franch,et al. Getting to the Meat of the Matter: Beyond Protein Supplementation in Maintenance Dialysis , 2009, Seminars in dialysis.
[2] D. Torre,et al. Serum Citrate Levels, Haptoglobin Haplotypes and Transferrin Receptor (CD71) in Patients With HIV-1 Infection , 2002, Infection.
[3] André M. N. Silva,et al. Influence of non-enzymatic post-translation modifications on the ability of human serum albumin to bind iron. Implications for non-transferrin-bound iron speciation. , 2009, Biochimica et biophysica acta.
[4] R. J. Hilton,et al. The ferroxidase center is essential for ferritin iron loading in the presence of phosphate and minimizes side reactions that form Fe(III)-phosphate colloids , 2011, BioMetals.
[5] D. C. Harris,et al. Facilitation of Fe(II) antoxidation by Fe(III) complexing agents , 1973 .
[6] Xiaole Kong,et al. Glutathione: a key component of the cytoplasmic labile iron pool , 2011, BioMetals.
[7] C. Winterbourn,et al. Radical-driven Fenton reactions: studies with paraquat, adriamycin, and anthraquinone 6-sulfonate and citrate, ATP, ADP, and pyrophosphate iron chelates. , 1987, Archives of biochemistry and biophysics.
[8] J. Himmelfarb,et al. Albumin is the major plasma protein target of oxidant stress in uremia. , 2001, Kidney international.
[9] P. Brissot,et al. Non-transferrin bound iron: a key role in iron overload and iron toxicity. , 2012, Biochimica et biophysica acta.
[10] E. Frieden,et al. A micromethod for the determination of ferroxidase (ceruloplasmin) in human serums. , 1967, Clinical chemistry.
[11] B. Kestenbaum,et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. , 2005, Journal of the American Society of Nephrology : JASN.
[12] M. Schlabach,et al. The reaction of ferric salts with transferrin. , 1973, The Journal of biological chemistry.
[13] R. Løvstad. Interaction of serum albumin with the Fe(III)-citrate complex. , 1993, The International journal of biochemistry.
[14] N. Vaziri,et al. Iatrogenic Iron Overload in Dialysis Patients at the Beginning of the 21st Century , 2016, Drugs.
[15] David G Levitt,et al. Human serum albumin homeostasis: a new look at the roles of synthesis, catabolism, renal and gastrointestinal excretion, and the clinical value of serum albumin measurements , 2016, International journal of general medicine.
[16] A. Bush,et al. A comparison of ceruloplasmin to biological polyanions in promoting the oxidation of Fe(2+) under physiologically relevant conditions. , 2014, Biochimica et biophysica acta.
[17] Z. Cabantchik. Labile iron in cells and body fluids: physiology, pathology, and pharmacology , 2014, Front. Pharmacol..
[18] Tyson Terpstra,et al. The thermodynamic and binding properties of the transferrins as studied by isothermal titration calorimetry. , 2012, Biochimica et biophysica acta.
[19] P. Brissot,et al. Quantification of non-transferrin-bound iron in the presence of unsaturated transferrin. , 1999, Analytical biochemistry.
[20] T. T. Nielsen. Plasma citrate during submaximal and intermittent supramaximal exercise. , 1978, Scandinavian journal of clinical and laboratory investigation.
[21] Elizabeth C. Theil,et al. Fe(III).ATP complexes. Models for ferritin and other polynuclear iron complexes with phosphate. , 1985, The Journal of biological chemistry.
[22] A. Garg,et al. Chronic kidney disease and mortality risk: a systematic review. , 2006, Journal of the American Society of Nephrology : JASN.
[23] C. Zoccali. Cardiorenal risk as a new frontier of nephrology: research needs and areas for intervention. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[24] M. Wolf,et al. Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease , 2014, Nature Reviews Nephrology.
[25] B. Stockwell,et al. The role of iron and reactive oxygen species in cell death. , 2014, Nature Chemical Biology.
[26] R. Harkness,et al. ATP, ADP and AMP in plasma from peripheral venous blood. , 1984, Clinica chimica acta; international journal of clinical chemistry.
[27] R. Boyer,et al. Iron incorporation into apoferritin. The role of apoferritin as a ferroxidase. , 1986, The Journal of biological chemistry.
[28] M. Kruszewski,et al. Further evidence that oxidative stress may be a risk factor responsible for the development of atherosclerosis. , 2001, Free radical biology & medicine.
[29] Z. Cabantchik,et al. The assessment of serum nontransferrin-bound iron in chelation therapy and iron supplementation. , 2000, Blood.
[30] W. C. O'Neill,et al. Plasma pyrophosphate and vascular calcification in chronic kidney disease. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[31] J. Wernicke,et al. The Kinetics and Mechanism of Iron (III) Exchange between Chelates and Transferrin IV. THE REACTION OF TRANSFERRIN WITH IRON(III) NITRILOTRIACETATE , 1971 .
[32] A. Mason,et al. Human serum transferrin: a tale of two lobes. Urea gel and steady state fluorescence analysis of recombinant transferrins as a function of pH, time, and the soluble portion of the transferrin receptor , 2009, JBIC Journal of Biological Inorganic Chemistry.
[33] F. Polticelli,et al. Ceruloplasmin-ferroportin system of iron traffic in vertebrates. , 2014, World journal of biological chemistry.
[34] D. V. Van Wyck,et al. Labile iron in parenteral iron formulations: a quantitative and comparative study. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[35] Ajay K. Singh,et al. Ferric pyrophosphate citrate (Triferic™) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[36] D. Kosman,et al. Ferroportin and Exocytoplasmic Ferroxidase Activity Are Required for Brain Microvascular Endothelial Cell Iron Efflux* , 2013, The Journal of Biological Chemistry.
[37] S. Srichairatanakool,et al. Non‐transferrin‐bound iron induced by myeloablative chemotherapy , 1997, British journal of haematology.
[38] J. Małyszko,et al. Iron metabolism in kidney allograft recipients: still a mystery? , 2011, Transplantation proceedings.
[39] U. Çakatay,et al. Human serum albumin and its relation with oxidative stress. , 2013, Clinical laboratory.
[40] R. J. Hilton,et al. Phosphate inhibits in vitro Fe3+ loading into transferrin by forming a soluble Fe(III)-phosphate complex: a potential non-transferrin bound iron species. , 2012, Journal of inorganic biochemistry.
[41] K. Collard,et al. Non-transferrin-bound iron is associated with biomarkers of oxidative stress, inflammation and endothelial dysfunction in type 2 diabetes. , 2015, Journal of diabetes and its complications.
[42] R. Prabhu,et al. Serum non-transferrin bound iron in hemodialysis patients not receiving intravenous iron. , 2005, Clinica chimica acta; international journal of clinical chemistry.
[43] X. Correig,et al. Metabolomics Approach for Analyzing the Effects of Exercise in Subjects with Type 1 Diabetes Mellitus , 2012, PloS one.
[44] C. Rapisarda,et al. Nature of non-transferrin-bound iron: studies on iron citrate complexes and thalassemic sera , 2007, JBIC Journal of Biological Inorganic Chemistry.
[45] P. Brissot,et al. Determination of non-transferrin-bound iron in genetic hemochromatosis using a new HPLC-based method. , 2000, Journal of hepatology.
[46] Charles W Buffington,et al. Human plasma ATP concentration. , 2007, Clinical chemistry.
[47] D. Nelson,et al. Comparing soluble ferric pyrophosphate to common iron salts and chelates as sources of bioavailable iron in a Caco-2 cell culture model. , 2009, Journal of agricultural and food chemistry.
[48] C. Tseng. Mortality and causes of death in a national sample of diabetic patients in Taiwan. , 2004, Diabetes care.
[49] G. Sebastiani,et al. Pharmacological Targeting of the Hepcidin/Ferroportin Axis , 2016, Front. Pharmacol..
[50] P. Sadler,et al. Non-transferrin-bound iron in plasma or serum from patients with idiopathic hemochromatosis. Characterization by high performance liquid chromatography and nuclear magnetic resonance spectroscopy. , 1989, The Journal of biological chemistry.
[51] D. Kosman. Iron metabolism in aerobes: managing ferric iron hydrolysis and ferrous iron autoxidation. , 2013, Coordination chemistry reviews.
[52] C. Vulpe,et al. Hephaestin is a ferroxidase that maintains partial activity in sex-linked anemia mice. , 2004, Blood.
[53] Fu-Huang Lin,et al. Intradialytic aerobic cycling exercise alleviates inflammation and improves endothelial progenitor cell count and bone density in hemodialysis patients , 2016, Medicine.
[54] R. Hider. Nature of nontransferrin‐bound iron , 2002, European journal of clinical investigation.
[55] V. Carnevale,et al. Studies on citrate metabolism in normal subjects and kidney stone patients. , 1989, Mineral and electrolyte metabolism.
[56] Enzo Terreno,et al. The extraordinary ligand binding properties of human serum albumin , 2005, IUBMB life.